#23andme

#23andme

OpenSNP will shut down due to risks of genetic data misuse, especially following 23andMe's bankruptcy.

OpenSNP will shut down and delete all data in April due to privacy concerns.

The site was founded to allow user-uploaded genetic data, totaling nearly 13,000 users.

23andMe files for bankruptcy amid privacy concerns following a significant data breach affecting millions of customers.

State Sen. James Sanders urges 23andMe users to delete genetic data amid bankruptcy concerns over data security.

23andMe's DNA data from 15 million individuals is being auctioned, raising concerns about privacy versus potential scientific benefits.

23andMe has filed for Chapter 11 bankruptcy in light of financial distress, leadership changes, and a decline in at-home DNA testing demand.

23andMe experienced a dramatic decline in market value due to privacy concerns and changing public sentiment about genetic testing.

Anne Wojcicki stepped down as CEO of 23andMe amidst the company's bankruptcy protection filing.

23andMe settled a $30 million lawsuit due to a significant 2023 data breach affecting millions, including genetic monitoring for affected users.

23andMe faces uncertainty due to potential acquisitions and a recent data breach.

There is increasing user concern about data privacy in light of ownership changes.

23andMe is struggling to retain customers and remains unclear about the future of the data it has collected.

The company faces significant challenges with its current business model as customer engagement declines.

23andMe faces severe struggles, raising concerns about consumer genetic data and the future of the industry.

The US health-research community is facing unprecedented funding freezes due to the Trump administration's abrupt cancellation of NIH grant reviews.

Regulation is essential to protect personal and genetic data amidst uncertainties in biotech firms like 23andMe.

Customers can request deletion of their genetic data from 23andMe to protect their privacy amid financial worries about the company.

California Attorney General advises individuals to delete their genetic data from 23andMe due to the company's potential bankruptcy.

23andMe is settling a data breach lawsuit for $30 million, committing to improved cybersecurity measures for affected users.

The company denies mishandling user data despite admitting to a major breach affecting millions.

23andMe faces major challenges including a data breach, a lawsuit settlement, and plummeting stock prices, calling consumer data security into question.

23andMe settles $30M class action lawsuit over data breach affecting 6.9 million customers, providing compensation and security monitoring.

23andMe is considering selling its telehealth business due to financial difficulties and a significant data breach impact.

Major layoffs in the tech sector persist into 2024, with significant cuts from companies like 23andMe, AMD, and iRobot.

23andMe is restructuring, resulting in major layoffs and a shutdown of its therapeutics division to focus on its core business.

The company has seen a decline in valuation and faced significant challenges in recent years, including a major data breach.

23andMe is restructuring, laying off 40% of its workforce, and abandoning its therapeutics program amidst severe financial struggles.

23andMe is facing significant challenges, including stock plummeting and resignation of all independent directors, signaling potential decline in company viability.

Leadership turmoil at 23andMe highlighted by board resignations over strategic differences, particularly CEO Anne Wojcicki's vision for privatization.

The board of directors of 23andMe resigned due to disagreements over the company's strategic direction and the CEO's management decisions.

23andMe appointed three new independent directors after all previous members resigned, highlighting challenges including consumer privacy concerns and declining stock values.

23andMe's board crisis reflects a struggle for strategic direction between CEO Anne Wojcicki and resigning directors amidst financial instability.

The entire board of 23andMe resigned due to differences in views with CEO Anne Wojcicki regarding plans to take the company private.